查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
肝癌診斷市場規模、份額和趨勢分析報告：按測試類型（實驗室測試、成像、內窺鏡檢查、活檢）、最終用途、地區、細分市場預測 2023-2030 年
市場調查報告書
商品編碼
1178637

肝癌診斷市場規模、份額和趨勢分析報告：按測試類型（實驗室測試、成像、內窺鏡檢查、活檢）、最終用途、地區、細分市場預測 2023-2030 年

Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Laboratory Tests, Imaging, Endoscopy, Biopsy), By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

肝癌診斷市場的增長和趨勢

根據 Grand View Research, Inc. 的最新報告，全球肝癌診斷市場規模在 2023 年至 2030 年的預測期內將以 6.67% 的複合年增長率增長，到 2030 年將達到 146.7 億美元。據報導預計將達到肝癌患病率的增加、診斷技術的進步以及對篩查治療和生存重要性的認識正在推動肝癌診斷市場的增長。

根據美國癌症協會的統計數據，預計 2022 年將診斷出約 41,260 例肝癌新病例。2020年，Globocan宣布全球約有830,180人死於肝癌。世衛組織還估計，慢性肝炎病毒感染在人群中很普遍，丙型肝炎病毒 (HCV) 影響了大約 5800 萬人。HCV 和乙型肝炎病毒 (HBV) 是肝癌最常見的相關危險因素。此外，肝硬化和吸煙等其他危險因素的流行增加了對早期治療和診斷肝癌以提高生存率的篩查解決方案的需求。因此，在預測期內對診斷的需求將上升，推動市場增長。

COVID-19 大流行擾亂了肝癌患者的治療並導致高死亡率。篩查和治療的延誤和中斷影響了該病患者。例如，在 2021 年 6 月的一篇論文中，來自歐洲國家的研究人員評估了大流行對肝癌患者常規護理的影響，並得出結論認為修正案顯著改變了結果。然而，在 COVID-19 期間技術的進步和對免疫系統的了解導致許多新的醫療保健診斷產品的推出。此外，大流行病提高了健康的重要性，定期進行健康檢查以早期診斷和治療已滲透到人群中。

世界各地許多公共和私營組織的提高認識和宣傳工作推動了診斷技術的進步。因此，有望為增加篩查和診斷各種癌症創造環境，促進診斷解決方案的發展。例如，2022 年 9 月，總部位於美國的診斷公司 Delfi Diagnostics, Inc. 宣布已被選為歐洲大規模篩查試驗的液體活檢合作夥伴。

一些公司正在推出新產品，以滿足對肝癌早期檢測創新解決方案日益增長的需求。例如，2020 年 3 月，F. Hoffmann-La Roche（以下簡稱 F.Roche）以新的 Elecsys GALAD 評分獲得了美國 FDA 的“突破性設備指定”。該評分通過為臨床醫生提供及時準確的信息來支持肝細胞癌 (HCC) 的診斷。大公司也在為新產品開發尋求聯合研究、協議和夥伴關係。此類產品的開發和推出將加劇市場競爭，刺激肝癌診斷市場的增長。

肝癌診斷市場亮點

按測試類型劃分，由於對準確且具有成本效益的疾病階段診斷的需求不斷增長，實驗室測試將在 2022 年佔據最大份額。此外，用於監測對治療方案的反應的實驗室測試的應用也推動了增長。

按最終用途劃分，醫院和診斷實驗室部分在 2022 年主導了市場。在醫療專業人員的幫助下，對這些環境作為初級保健中心進行診斷和治療的偏好正在推動這一領域的增長。

由於人口中普遍存在風險因素，北美將在 2022 年佔據最高份額。這是由於該地區對疾病篩查的認識不斷提高，以及越來越多地採用先進技術，這推動了增長。

由於疾病流行和大量老年人口的存在，預計亞太地區在 2023 年至 2030 年的預測期內將出現最快的增長。新興經濟體還將推動該地區新興經濟體採用診斷測試。

目錄

第一章 調查方法和範圍

  • 調查方法
  • 調查假設
  • 信息採購
    • 購買的數據庫
    • GVR內部數據庫
    • 次要信息
    • 初步調查
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證

第二章執行摘要

  • 市場快照
  • 段快照
  • 競爭格局的快照

3. 市場變量、趨勢和範圍

  • 母市場分析
  • 市場動態
    • 市場驅動力分析
      • 肝癌患病率增加
      • 公共和私人機構舉措的增加
      • 肝癌危險因素的患病率增加
      • 技術進步
    • 市場約束因素分析
      • 影像診斷費用高
      • 輻射暴露可能會限制 Ct 的使用
  • 繪製滲透率和增長前景
  • 肝癌診斷市場-波特分析
  • 肝癌診斷市場-SWOT 分析
  • COVID-19 影響分析

第四章檢驗類業務分析

  • 肝癌診斷市場-測試類型的變化分析
  • 臨床檢查
    • 生物標誌物
      • 癌胚抗原和糖蛋白抗原
      • □和同工□
      • 生長因子和受體
      • 分子標記
      • 病理生物標誌物
    • 驗血
  • 成像
  • 內窺鏡檢查
  • 活檢
  • 其他

第 5 章最終用途業務分析

  • 肝癌診斷市場-最終用途趨勢分析
  • 醫院和診斷實驗室
  • 學術/研究機構
  • 製藥和氯實驗室

第六章區域業務分析

  • 肝癌診斷市場：區域趨勢分析
  • 北美
    • SWOT分析
    • 美國
      • 主要國家動態
      • 競爭情景
      • 美國肝癌診斷市場，2018-2030（百萬美元）
  • 歐洲
    • SWOT分析
    • 英國
      • 主要國家動態
      • 競爭情景
      • 英國肝癌診斷市場，2018-2030（百萬美元）
    • 德國
      • 主要國家動態
      • 競爭情景
      • 德國肝癌診斷市場，2018-2030（百萬美元）
    • 法國
      • 主要國家動態
      • 競爭情景
      • 法國肝癌診斷市場，2018-2030（百萬美元）
    • 意大利
      • 主要國家動態
      • 競爭情景
      • 意大利肝癌診斷市場，2018-2030（百萬美元）
    • 西班牙
      • 主要國家動態
      • 競爭情景
      • 西班牙肝癌診斷市場，2018-2030（百萬美元）
    • 丹麥
      • 主要國家動態
      • 競爭情景
      • 丹麥肝癌診斷市場，2018-2030（百萬美元）
    • 瑞典
      • 主要國家動態
      • 競爭情景
      • 瑞典肝癌診斷市場，2018-2030（百萬美元）
    • 挪威
      • 主要國家動態
      • 競爭情景
      • 挪威肝癌診斷市場，2018-2030（百萬美元）
    • 歐洲其他地區
      • 主要國家動態
      • 競爭情景
      • 其他歐洲肝癌診斷市場，2018-2030（百萬美元）
  • 亞太地區
    • SWOT分析
    • 日本
      • 主要國家動態
      • 競爭情景
      • 日本肝癌診斷市場，2018-2030（百萬美元）
    • 中國
      • 主要國家動態
      • 競爭情景
      • 中國肝癌診斷市場，2018-2030（百萬美元）
    • 印度
      • 主要國家動態
      • 競爭情景
      • 印度肝癌診斷市場，2018-2030（百萬美元）
    • 韓國
      • 主要國家動態
      • 競爭情景
      • 韓國肝癌診斷市場，2018-2030（百萬美元）
    • 澳大利亞
      • 主要國家動態
      • 競爭情景
      • 澳大利亞肝癌診斷市場，2018-2030（百萬美元）
    • 泰國
      • 主要國家動態
      • 競爭情景
      • 泰國肝癌診斷市場，2018-2030（百萬美元）
    • 亞太其他地區
      • 主要國家動態
      • 競爭情景
      • 亞太地區其他肝癌診斷市場，2018-2030（百萬美元）
  • 拉丁美洲
    • SWOT分析
    • 巴西
      • 主要國家動態
      • 競爭情景
      • 巴西肝癌診斷市場，2018-2030（百萬美元）
    • 墨西哥
      • 主要國家動態
      • 競爭情景
      • 墨西哥肝癌診斷市場，2018-2030（百萬美元）
    • 阿根廷
      • 主要國家動態
      • 競爭情景
      • 阿根廷肝癌診斷市場，2018-2030（百萬美元）
    • 其他拉丁美洲
      • 主要國家動態
      • 競爭情景
      • 拉丁美洲其他地區肝癌診斷市場，2018-2030（百萬美元）
  • 中東和非洲（Mea）
    • SWOT分析
    • 南非
      • 主要國家動態
      • 競爭情景
      • 南非肝癌診斷市場，2018-2030（百萬美元）
    • 阿拉伯聯合酋長國
      • 主要國家動態
      • 競爭情景
      • 阿拉伯聯合酋長國肝癌診斷市場，2018-2030（百萬美元）
    • 科威特
      • 主要國家動態
      • 競爭情景
      • 科威特肝癌診斷市場，2018-2030（百萬美元）
    • 其他中東/非洲
      • 主要國家動態
      • 競爭情景
      • 中東和非洲其他地區肝癌診斷市場，2018-2030（百萬美元）

第七章競爭格局

  • 參賽者概覽
    • Abbott Laboratories
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Qiagen N.V.
    • Seimens Healthineers
    • Becton, Dickinson & Company
    • Fujifilm Medical Systems U.S.A., Inc.
    • Illumina, Inc.
    • Epigenomics Ag
    • Koninklijke Philips N.V.
  • 財務績效
  • 進入公司
    • 市場領導者
      • 2022 年肝癌診斷市場份額分析
    • 戰略規劃
      • 擴張
      • 獲得
      • 合作
      • 產品/服務發布
      • 合夥
      • 其他
Product Code: GVR-3-68038-012-5

Liver Cancer Diagnostics Market Growth & Trends:

The global liver cancer diagnostics market size is expected to reach USD 14.67 billion by 2030, advancing at a CAGR of 6.67% over the forecast period from 2023 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of liver cancer, the technological advancements for diagnosis, and the awareness of screening importance for treatment & survival rate are driving the market growth for liver cancer diagnostics.

According to the American Society of Cancer statistics in 2022, around 41,260 new cases are expected to be diagnosed with liver cancer. It was also presented by Globocan in 2020, that about 830,180 deaths were accounted by liver cancer worldwide. WHO also estimates that chronic hepatitis viral infections are widespread in the population, with hepatitis C virus (HCV) affecting about 58 million people. HCV and hepatitis B virus (HBV) are the most commonly associated risk factors of liver cancer. In addition, the infection prevalence and exposure to other risk factors such as cirrhosis and smoking will upsurge the demand for screening solutions for early treatment & diagnosis of liver cancer to increase the survival rate. Thus, the demand for diagnostics products will boost during the forecast period, thereby driving market growth.

The COVID-19 pandemic disrupted liver cancer patient care and resulted in higher mortality rates. The delayed or interrupted screening & procedures impacted the patients with the disease. For example, in a June 2021 article, researchers from European countries assessed the pandemic's impact on routine care of liver cancer patients and concluded that the modifications significantly altered the outcomes. However, with advancements in technology and a better understanding of the immune system during COVID-19, many new healthcare diagnostic products have been launched. Moreover, the pandemic boosted the importance of health and pushed the population toward regular health screening for early diagnosis & treatment.

The technological advancement in diagnosis has resulted from increased awareness and supportive initiatives by many public-private organizations worldwide. This will result in a conducive environment to increase the screening as well as diagnosis of various cancers and is expected to propel the growth of diagnostics solutions. For example, in September 2022, Delfi Diagnostics, Inc., a U.S.-based diagnostics company, announced that it has been selected as the liquid biopsy partner in a large-scale screening trial in Europe.

To cater to the increased demand for innovative solutions for the early detection of liver cancer, multiple companies are launching new products. For instance, in March 2020, F. Hoffmann-La Roche Ltd. Roche received the 'Breakthrough Device Designation' from the US FDA for its new Elecsys GALAD score. The score supports clinicians in the diagnosis of hepatocellular carcinoma (HCC) by providing them with timely and accurate information. Key companies are also undergoing collaborations, agreements, and partnerships for new product developments. Such product developments & launches will intensify the market competition and fuel the market growth for liver cancer diagnostics.

Liver Cancer Diagnostics Market Report Highlights:

  • On basis of test type, laboratory tests held the largest share in 2022, owing to the increased demand for accurate & cost-effective diagnosis of disease stages. In addition, the application of laboratory tests for monitoring response to treatment plans also propels the growth
  • Based on end-use, the hospitals and diagnostic laboratories segment dominated the market in 2022. The preference for these settings as primary care centers for the diagnosis and treatment with the help of medical professionals boosts the segment's growth
  • North America accounted for the highest share in 2022 due to the prevalence of risk factors in the population. This has resulted from the increased awareness about disease screening and the growing adoption of advanced technologies in this region, driving the growth
  • Asia Pacific will exhibit the fastest growth during the forecast period of 2023-2030, owing to the prevalence of diseases and the presence of a large geriatric population in the region. In addition, the developing economies will boost the adoption of diagnostic tests in the region's emerging countries

Table of Contents

Chapter 1 Methodology And Scope

  • 1.1 Research Methodology
  • 1.2 Research Assumptions
    • 1.2.1 Estimates And Forecast Timeline
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Landscape Snapshot

Chapter 3 Market Variables, Trends, & Scope

  • 3.1 Parent Market Analysis
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Increasing Prevalence Of Liver Cancer
      • 3.2.1.2 Rising Initiatives Undertaken By Public And Private Organizations
      • 3.2.1.3 Increasing Prevalence Of Risk Factors For Liver Cancer
      • 3.2.1.4 Technological Advancements
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 High Cost Of Diagnostic Imaging
      • 3.2.2.2 Radiation Exposure Likely To Limit Usage Of Ct
  • 3.3 Penetration & Growth Prospect Mapping
  • 3.4 Liver Cancer Diagonstics Market - Porter's Analysis
  • 3.5 Liver Cancer Diagonstics Market - Swot Analysis
  • 3.6 Covid-19 Impact Analysis

Chapter 4 Test Type Business Analysis

  • 4.1 Liver Cancer Diagonstics Market - Test Type Movement Analysis
  • 4.2 Laboratory Tests
    • 4.2.1 Global Laboratory Tests Market, 2018 - 2030 (USD Million)
    • 4.2.2 Biomarkers
      • 4.2.2.1 Global Biomarkers Market, 2018 - 2030 (USD Million)
      • 4.2.2.2 Oncofetal And Glycoprotein Antigens
      • 4.2.2.2.1 Global Oncofetal And Glycoprotein Antigens Market, 2018 - 2030 (USD Million)
      • 4.2.2.3 Enzymes And Isoenzymes
      • 4.2.2.3.1 Global Enzymes And Isoenzymes Market, 2018 - 2030 (USD Million)
      • 4.2.2.4 Growth Factors And Receptors
      • 4.2.2.4.1 Global Growth Factors And Receptors Market, 2018 - 2030 (USD Million)
      • 4.2.2.5 Molecular Markers
      • 4.2.2.5.1 Global Molecular Markers Market, 2018 - 2030 (USD Million)
      • 4.2.2.6 Pathological Biomarkers
      • 4.2.2.6.1 Global Pathological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.2.3 Blood Tests
      • 4.2.3.1 Global Bloos Tests Market, 2018 - 2030 (USD Million)
  • 4.3 Imaging
    • 4.3.1 Global Imaging Market, 2018 - 2030 (USD Million)
  • 4.4 Endoscopy
    • 4.4.1 Global Endoscopy Market, 2018 - 2030 (USD Million)
  • 4.5 Biopsy
    • 4.5.1 Global Biopsy Market, 2018 - 2030 (USD Million)
  • 4.6 Others
    • 4.6.1 Global Other Tests Type Market, 2018 - 2030 (USD Million)

Chapter 5 End-Use Business Analysis

  • 5.1 Liver Cancer Diagonstics Market-End Use Movement Analysis
  • 5.2 Hospitals & Diagnostic Laboratories
    • 5.2.1 Global Hospitals & Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
  • 5.3 Academic & Research Institutes
    • 5.3.1 Global Academic & Research Institutes Market, 2018 - 2030 (USD Million)
  • 5.4 Pharmaceutical & Cro Laboratories
    • 5.4.1 Global Pharmaceutical & Cro Laboratories Market, 2018 - 2030 (USD Million)

Chaper 6 Regional Business Analysis

  • 6.1 Liver Cancer Diagonstics Market: Regional Movement Analysis
  • 6.2 North America
    • 6.2.1 Swot Analysis
      • 6.2.1.1 North America Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.2 U.S.
      • 6.2.2.1 Key Country Dynamics
      • 6.2.2.2 Competitive Scenario
      • 6.2.2.3 U.S. Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.2.3 Rest Of Europe
      • 6.2.3.1 Key Country Dynamics
      • 6.2.3.2 Competitive Scenario
      • 6.2.3.3 Rest Of Europe Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
  • 6.3 Europe
    • 6.3.1 Swot Analysis
      • 6.3.1.1 Europe Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.3.2 U.K.
      • 6.3.2.1 Key Country Dynamics
      • 6.3.2.2 Competitive Scenario
      • 6.3.2.3 U.K. Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.3.3 Germany
      • 6.3.3.1 Key Country Dynamics
      • 6.3.3.2 Competitive Scenario
      • 6.3.3.3 Germany Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.3.4 France
      • 6.3.4.1 Key Country Dynamics
      • 6.3.4.2 Competitive Scenario
      • 6.3.4.3 France Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.3.5 Italy
      • 6.3.5.1 Key Country Dynamics
      • 6.3.5.2 Competitive Scenario
      • 6.3.5.3 Italy Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.3.6 Spain
      • 6.3.6.1 Key Country Dynamics
      • 6.3.6.2 Competitive Scenario
      • 6.3.6.3 Spain Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.3.7 Denmark
      • 6.3.7.1 Key Country Dynamics
      • 6.3.7.2 Competitive Scenario
      • 6.3.7.3 Denmark Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.3.8 Sweden
      • 6.3.8.1 Key Country Dynamics
      • 6.3.8.2 Competitive Scenario
      • 6.3.8.3 Sweden Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.3.9 Norway
      • 6.3.9.1 Key Country Dynamics
      • 6.3.9.2 Competitive Scenario
      • 6.3.9.3 Norway Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.3.10 Rest Of Europe
      • 6.3.10.1 Key Country Dynamics
      • 6.3.10.2 Competitive Scenario
      • 6.3.10.3 Rest Of Europe Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Swot Analysis
      • 6.4.1.1 Asia Pacific Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.4.2 Japan
      • 6.4.2.1 Key Country Dynamics
      • 6.4.2.2 Competitive Scenario
      • 6.4.2.3 Japan Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.4.3 China
      • 6.4.3.1 Key Country Dynamics
      • 6.4.3.2 Competitive Scenario
      • 6.4.3.3 China Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.4.4 India
      • 6.4.4.1 Key Country Dynamics
      • 6.4.4.2 Competitive Scenario
      • 6.4.4.3 India Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.4.5 South Korea
      • 6.4.5.1 Key Country Dynamics
      • 6.4.5.2 Competitive Scenario
      • 6.4.5.3 South Korea Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.4.6 Australia
      • 6.4.6.1 Key Country Dynamics
      • 6.4.6.2 Competitive Scenario
      • 6.4.6.3 Australia Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.4.7 Thailand
      • 6.4.7.1 Key Country Dynamics
      • 6.4.7.2 Competitive Scenario
      • 6.4.7.3 Thailand Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.4.8 Rest Of Asia Pacific
      • 6.4.8.1 Key Country Dynamics
      • 6.4.8.2 Competitive Scenario
      • 6.4.8.3 Rest Of Apac Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Swot Analysis
      • 6.5.1.1 Latin America Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.5.2 Brazil
      • 6.5.2.1 Key Country Dynamics
      • 6.5.2.2 Competitive Scenario
      • 6.5.2.3 Brazil Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.5.3 Mexico
      • 6.5.3.1 Key Country Dynamics
      • 6.5.3.2 Competitive Scenario
      • 6.5.3.3 Mexico Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.5.4 Argentina
      • 6.5.4.1 Key Country Dynamics
      • 6.5.4.2 Competitive Scenario
      • 6.5.4.3 Argentina Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.5.5 Rest Of Latin America
      • 6.5.5.1 Key Country Dynamics
      • 6.5.5.2 Competitive Scenario
      • 6.5.5.3 Rest Of Latam Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
  • 6.6 Middle East & Africa (Mea)
    • 6.6.1 Swot Analysis
      • 6.6.1.1 Mea Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.6.2 South Africa
      • 6.6.2.1 Key Country Dynamics
      • 6.6.2.2 Competitive Scenario
      • 6.6.2.3 South Africa Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.6.3 Rest Of Middle East & Africa
      • 6.6.3.1 Key Country Dynamics
      • 6.6.3.2 Competitive Scenario
      • 6.6.3.3 Rest Of Middle East & Africa Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.6.4 Uae
      • 6.6.4.1 Key Country Dynamics
      • 6.6.4.2 Competitive Scenario
      • 6.6.4.3 Uae Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.6.5 Kuwait
      • 6.6.5.1 Key Country Dynamics
      • 6.6.5.2 Competitive Scenario
      • 6.6.5.3 Kuwait Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.6.6 Rest Of Mea
      • 6.6.6.1 Key Country Dynamics
      • 6.6.6.2 Competitive Scenario
      • 6.6.6.3 Rest Of Mea Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Participant's Overview
    • 7.1.1 Abbott Laboratories
    • 7.1.2 Thermo Fisher Scientific, Inc.
    • 7.1.3 F. Hoffmann-La Roche Ltd.
    • 7.1.4 Qiagen N.V.
    • 7.1.5 Seimens Healthineers
    • 7.1.6 Becton, Dickinson & Company
    • 7.1.7 Fujifilm Medical Systems U.S.A., Inc.
    • 7.1.8 Illumina, Inc.
    • 7.1.9 Epigenomics Ag
    • 7.1.10 Koninklijke Philips N.V.
  • 7.2 Financial Performance
  • 7.3 Participant Categorization
    • 7.3.1 Market Leaders
      • 7.3.1.1 Liver Cancer Diagnostics Market Share Analysis, 2022
    • 7.3.2 Strategy Mapping
      • 7.3.2.1 Expansion
      • 7.3.2.2 Acquisition
      • 7.3.2.3 Collaborations
      • 7.3.2.4 Product/Service Launch
      • 7.3.2.5 Partnerships
      • 7.3.2.6 Others

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 4 Global liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 Global liver cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 6 North America liver cancer diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 8 North America liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 U.S. liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 10 U.S. liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 11 Rest of Europe liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 12 Rest of Europe liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 13 Europe liver cancer diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 14 Europe liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 15 Europe liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 U.K. liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 17 U.K. liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 18 Germany liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 19 Germany liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 France liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 21 France liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 Italy liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 23 Italy liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 Spain liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 25 Spain liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Denmark liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 27 Denmark liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Sweden liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 29 Sweden liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 30 Norway liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 31 Norway liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific liver cancer diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 Japan liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 36 Japan liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 China liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 38 China liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 39 India liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 40 India liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 South Korea liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 42 South Korea liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Australia liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 44 Australia liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 45 Thailand liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 46 Thailand liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 Latin America liver cancer diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 48 Latin America liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 49 Latin America liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 Brazil liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 51 Brazil liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 52 Mexico liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 53 Mexico liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 54 Argentina liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 55 Argentina liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa liver cancer diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 South Africa liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 60 South Africa liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 61 Rest of Middle East & Africa liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 62 Rest of Middle East & Africa liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 63 UAE liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 64 UAE liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 65 Kuwait liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 66 Kuwait liver cancer diagnostics, by end-use, 2018 - 2030 (USD Million)
  • Table 67 Participant's overview
  • Table 68 Financial performance
  • Table 69 Key companies undergoing expansions
  • Table 70 Key companies undertaking acquisitions
  • Table 71 Key companies undergoing collaborations
  • Table 72 Key companies launching new products/services
  • Table 73 Key companies undergoing partnerships
  • Table 74 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market summary, 2022 (USD Million)
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Market driver impact
  • Fig. 11 Market restraint impact
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Porter's analysis
  • Fig. 14 SWOT analysis
  • Fig. 15 Liver cancer diagnostics market: Test type outlook and key takeaways
  • Fig. 16 Liver cancer diagnostics market: Test type movement analysis
  • Fig. 17 Global oncofetal and glycoprotein antigens market, 2018 - 2030 (USD Million)
  • Fig. 18 Global enzymes and isoenzymes market, 2018 - 2030 (USD Million)
  • Fig. 19 Global growth factors and receptors market, 2018 - 2030 (USD Million)
  • Fig. 20 Global molecular markers readers market, 2018 - 2030 (USD Million)
  • Fig. 21 Global pathological biomarkers market, 2018 - 2030 (USD Million)
  • Fig. 22 Global blood tests market, 2018 - 2030 (USD Million)
  • Fig. 23 Global imaging market, 2018 - 2030 (USD Million)
  • Fig. 24 Global endoscopy market, 2018 - 2030 (USD Million)
  • Fig. 25 Global biopsy market, 2018 - 2030 (USD Million)
  • Fig. 26 Global other tests type market, 2018 - 2030 (USD Million)
  • Fig. 27 Liver cancer diagnostics market: End-use outlook and key takeaways
  • Fig. 28 Liver cancer diagnostics market: End-use movement analysis
  • Fig. 29 Global hospitals & diagnostic laboratories market, 2018 - 2030 (USD Million)
  • Fig. 30 Global academic & research institutes market, 2018 - 2030 (USD Million)
  • Fig. 31 Global pharmaceutical & CRO laboratories market, 2018 - 2030 (USD Million)
  • Fig. 32 Liver cancer diagnostics market: Regional outlook and key takeaways
  • Fig. 33 North America: SWOT Analysis
  • Fig. 34 North America liver cancer diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 35 US key country dynamics
  • Fig. 36 US liver cancer diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 37 Rest of Europe key country dynamics
  • Fig. 38 Rest of Europe liver cancer diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 39 Europe: SWOT Analysis
  • Fig. 40 Europe liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 UK key country dynamics
  • Fig. 42 UK liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Germany key country dynamics
  • Fig. 44 Germany liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 France key country dynamics
  • Fig. 46 France liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Italy key country dynamics
  • Fig. 48 Italy liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Spain key country dynamics
  • Fig. 50 Spain liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark key country dynamics
  • Fig. 52 Denmark liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden key country dynamics
  • Fig. 54 Sweden liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Norway key country dynamics
  • Fig. 56 Norway liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Rest of Europe key country dynamics
  • Fig. 58 Rest of Europe liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Asia-Pacific: SWOT Analysis
  • Fig. 60 Asia-Pacific liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Japan key country dynamics
  • Fig. 62 Japan liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 China key country dynamics
  • Fig. 64 China liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 India key country dynamics
  • Fig. 66 India liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea key country dynamics
  • Fig. 68 South Korea liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Australia key country dynamics
  • Fig. 70 Australia liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 71 Thailand key country dynamics
  • Fig. 72 Thailand liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Rest of Asia Pacific key country dynamics
  • Fig. 74 Rest of Asia Pacific liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Latin America: SWOT Analysis
  • Fig. 76 Latin America liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 Brazil key country dynamics
  • Fig. 78 Brazil liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Mexico key country dynamics
  • Fig. 80 Mexico liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina key country dynamics
  • Fig. 82 Argentina liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Rest of Latin America key country dynamics
  • Fig. 84 Rest of Latin America liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Middle East & Africa: SWOT Analysis
  • Fig. 86 Middle East & Africa liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 87 South Africa key country dynamics
  • Fig. 88 South Africa liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 89 Rest of Middle East & Africa key country dynamics
  • Fig. 90 Rest of Middle East & Africa liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 91 UAE key country dynamics
  • Fig. 92 UAE liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 93 Kuwait key country dynamics
  • Fig. 94 Kuwait liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 95 Rest of Middle East & Africa key country dynamics
  • Fig. 96 Rest of Middle East & Africa liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 97 Heat map analysis
  • Fig. 98 Market participant categorization
  • Fig. 99 Liver cancer diagnostics market share analysis, 2022
  • Fig. 100 Strategy framework